Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness.

Trial Profile

Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness.

Not stated
Phase of Trial: Phase IV

Latest Information Update: 23 Aug 2012

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Warfarin
  • Indications Stroke; Thromboembolism
  • Focus Therapeutic Use
  • Acronyms RE-LY; ROCKET-AF
  • Most Recent Events

    • 23 Aug 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top